Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Patients treated for rhabdomyosarcoma (RMS) or Ewing sarcoma (ES) are subject to extensive follow-up after completion of therapy. The aim of this follow-up is to monitor treatment side effects and to detect relapse in an early phase to improve prognosis after relapse. Little is known about parental emotional experiences during this period. We assessed the views and experiences of parents of children treated for RMS or ES on the follow-up examinations after completion of therapy.
We conducted two focus group meetings and four semi-structured telephone interviews with parents of children treated for RMS or ES in Dutch pediatric oncology centers. Parents of children 0–5 years after end-of-therapy were invited via letters (response rate 31%) and via social media channels of “Dutch Childhood Association for Children and Parents” (VOKK). An inductive thematic approach was used to analyze the data.
In total, 12 parents (fathers, n = 3; mothers, n = 9) of 12 patients treated for RMS (n = 6) or ES (n = 6) participated. Median age at diagnosis for their children was 7.9 years and median time after end-of-treatment was 37 months. Four major themes were identified: content of follow-up, distress and anxiety, search for reassurance and hope, and interaction with others. Parents of children treated for RMS or ES report experiencing significant distress after completion of treatment. They report that their distress was decreased by adequate communication about content, timing, and reasoning behind follow-up.
Physicians should pay attention to the needs of individual parents to reduce distress in the period after completion of therapy.
Bisogno G, Jenney M, Bergeron C, Gallego Melcon S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL, European paediatric Soft tissue sarcoma Study G (2018) Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19(8):1061–1071. https://doi.org/10.1016/S1470-2045(18)30337-1 CrossRefPubMed
Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Kohler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jurgens H, European Intergroup Cooperative Ewing's Sarcoma S (2008) Results of the EICESS-92 study: two randomized trials of Ewing’s sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26(27):4385–4393. https://doi.org/10.1200/JCO.2008.16.5720 CrossRefPubMed
Chisholm JC, Marandet J, Rey A, Scopinaro M, de Toledo JS, Merks JH, O'Meara A, Stevens MC, Oberlin O (2011) Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 29(10):1319–1325. https://doi.org/10.1200/JCO.2010.32.1984 CrossRefPubMed
Ferrari S, Luksch R, Hall KS, Fagioli F, Prete A, Tamburini A, Tienghi A, DiGirolamo S, Paioli A, Abate ME, Podda M, Cammelli S, Eriksson M, Brach del Prever A (2015) Post-relapse survival in patients with Ewing sarcoma. Pediatr Blood Cancer 62(6):994–999. https://doi.org/10.1002/pbc.25388 CrossRefPubMed
Vaarwerk B, Mallebranche C, Affinita MC, Adams MR, Van Der Lee JH, Jenney M, Ferrari A, Chisholm JC, Defachelle AS, Corradini N, Minard-Colin V, McHugh K, Bisogno G, Van Rijn R, Orbach D, Merks JHM (2018) Does surveillance imaging lead to earlier detection of relapse and thus to improved survival in paediatric patients with rhabdomyosarcoma? The European experience. Pediatric Radiol 48(supplement 2):S489–S490. https://doi.org/10.1007/s00247-018-4151-7 CrossRef
Heinemann M, Ranft A, Langer T, Jurgens H, Kreyer J, Vieth V, Schafers M, Weckesser M, Simon T, Hassenpflug W, Corbacioglu S, Bielack S, Mayer-Steinacker R, Kuhne T, van den Berg H, Gelderblom H, Bauer S, Stegger L, Dirksen U (2018) Recurrence of Ewing sarcoma: is detection by imaging follow-up protocol associated with survival advantage? Pediatr Blood Cancer 65(7):e27011. https://doi.org/10.1002/pbc.27011 CrossRefPubMed
Brok J, Lopez-Yurda M, Tinteren HV, Treger TD, Furtwängler R, Graf N, Bergeron C, van den Heuvel-Eibrink MM, Pritchard-Jones K, Olsen ØE, de Camargo B, Verschuur A, Spreafico F (2018) Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group–International Society of Paediatric Oncology Wilms' tumour protocol database. Lancet Oncol 19:1072–1081. https://doi.org/10.1016/s1470-2045(18)30293-6 CrossRefPubMed
Punyko JA, Gurney JG, Scott Baker K, Hayashi RJ, Hudson MM, Liu Y, Robison LL, Mertens AC (2007) Physical impairment and social adaptation in adult survivors of childhood and adolescent rhabdomyosarcoma: a report from the Childhood Cancer Survivors Study. Psychooncology 16(1):26–37. https://doi.org/10.1002/pon.1072 CrossRefPubMed
Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA, Raney RB, Stovall M, Sklar CA, Robison LL, Baker KS (2005) Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer 44(7):643–653. https://doi.org/10.1002/pbc.20310 CrossRefPubMed
Quin S (2004) The long-term psychosocial effects of cancer diagnosis and treatment on children and their families. Soc Work Health Care 39(1–2):129–149 PubMed
Koocher GP, O'Malley JE (1981) The Damocles syndrome: psychological consequences of surviving childhood cancer. McGraw-Hill, New York (N.Y.)
Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, Childhood Cancer Survivor S (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355(15):1572–1582. https://doi.org/10.1056/NEJMsa060185 CrossRefPubMed
Grootenhuis MA, Bronner MB (2009) Paediatric illness! Family matters. Acta Paediatr 98(6):940–941
Mu PF, Lee MY, Sheng CC, Tung PC, Huang LY, Chen YW (2015) The experiences of family members in the year following the diagnosis of a child or adolescent with cancer: a qualitative systematic review. JBI Database System Rev Implement Rep 13(5):293–329. https://doi.org/10.11124/jbisrir-2015-1698 CrossRefPubMed
Vetsch J, Fardell JE, Wakefield CE, Signorelli C, Michel G, JK ML, Walwyn T, Tapp H, Truscott J, Cohn RJ, group Ass (2017) “forewarned and forearmed”: long-term childhood cancer survivors’ and parents' information needs and implications for survivorship models of care. Patient Educ Couns 100(2):355–363. https://doi.org/10.1016/j.pec.2016.09.013 CrossRefPubMed
Kastel A, Enskar K, Bjork O (2011) Parents’ views on information in childhood cancer care. Eur J Oncol Nurs 15(4):290–295. https://doi.org/10.1016/j.ejon.2010.10.007
Sisk BA, Mack JW, Ashworth R, DuBois J (2018) Communication in pediatric oncology: state of the field and research agenda. Pediatr Blood Cancer 65(1):e26727. https://doi.org/10.1002/pbc.26727
Mallebranche C, Carton M, Minard-Colin V, Desfachelle AS, Rome A, Brisse HJ, Mosseri V, Thebaud E, Pellier I, Boutroux H, Gandemer V, Corradini N, Orbach D (2017) Relapse after rhabdomyosarcoma in childhood and adolescence: impact of an early detection on survival. Bull Cancer 104(7–8):625–635. https://doi.org/10.1016/j.bulcan.2017.05.008 CrossRefPubMed
- Getting control during follow-up visits: the views and experiences of parents on tumor surveillance after their children have completed therapy for rhabdomyosarcoma or Ewing sarcoma
P. F. Limperg
M. C. Naafs-Wilstra
J. H. M. Merks
M. A. Grootenhuis
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II